|
| 36865101 | Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization. | | 2023 |
| 36334723 | Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons. | American journal of obstetrics & gynecology MFM | 2023 |
| 37903160 | Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization. | | 2023 |
| 37563124 | SARS-CoV-2 vaccination, booster, and infection in pregnant population enhances passive immunity in neonates. | Nat Commun | 2023 |
| 37384638 | Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study. | | 2023 |
| 37244989 | Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization. | | 2023 |
| 34669426 | The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. | Journal of Virology | 2022 |
| 35932217 | Asthma 17q21 polymorphism associates with decreased risk of COVID-19 in children. | Pediatric Pulmonology | 2022 |
| 36597532 | SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemia. | | 2022 |
| 34390501 | Serologic response to mRNA COVID-19 vaccination in lymphoma patients. | Am J Hematol | 2021 |
| 33524125 | Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health. | J Clin Endocrinol Metab | 2021 |
| 33515984 | Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. | Biosensors and Bioelectronics | 2021 |
| 34193339 | Predictors of Nonseroconversion after SARS-CoV-2 Infection. | Emerg Infect Dis | 2021 |
| 34136730 | Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. | Pathog Immun | 2021 |
| 33438580 | High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination. | eLife | 2021 |
| 33758842 | Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. | bioRxiv | 2021 |
| 33236020 | Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. | | 2020 |
| 32393800 | T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. | Nat Med | 2020 |
| 33521696 | Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. | Cell Rep Med | 2020 |
| 31537780 | Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. | Nat Commun | 2019 |
| 30487280 | Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. | J Virol | 2019 |
| 29150937 | cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. | Biotechnol Bioeng | 2018 |
| 29669838 | Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers . | Journal of Virology | 2018 |
| 29474444 | Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. | PLoS Pathog | 2018 |
| 28834745 | Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. | Cell Rep | 2017 |
| 28539451 | Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. | J Virol | 2017 |
| 27627672 | Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. | PLoS Pathog | 2016 |
| 27467575 | Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond. | PLoS Pathog | 2016 |
| 26246566 | Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. | Journal of Virology | 2015 |
| 25589637 | A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. | J Virol | 2015 |
| 26311893 | Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. | J Virol | 2015 |
| 26089353 | HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. | Science | 2015 |
| 24767177 | Stable 293Â T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies. | Retrovirology | 2014 |
| 23109186 | Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. | Journal of Antimicrobial Chemotherapy | 2013 |
| 24068931 | A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. | PLoS Pathog | 2013 |
| 22018634 | Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. | Virology | 2012 |
| 22330914 | Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. | Antimicrobial Agents and Chemotherapy | 2012 |
| 22524614 | Enhancement of α-helix mimicry by an α/β-peptide foldamer via incorporation of a dense ionic side-chain array. | Journal of the American Chemical Society | 2012 |
| 22666328 | A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity. | PLoS ONE | 2012 |
| 22520838 | Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance. | Virology | 2012 |
| 21690411 | Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. | Proceedings of the National Academy of Sciences of the United States of America | 2011 |
| 21356539 | Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. | Virology | 2011 |
| 20629537 | Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. | Journal of Infectious Diseases | 2010 |
| 19648924 | HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. | Nature Immunology | 2009 |
| 19410272 | Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. | Virology | 2009 |
| 19303620 | Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. | Virology | 2009 |
| 19297617 | Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. | Proceedings of the National Academy of Sciences of the United States of America | 2009 |
| 19289833 | Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. | Proceedings of the National Academy of Sciences of the United States of America | 2009 |
| 19706443 | Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. | Proceedings of the National Academy of Sciences of the United States of America | 2009 |
| 18647836 | Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. | Proceedings of the National Academy of Sciences of the United States of America | 2008 |